Introduction
Blood clots are a major cause of heart attacks, strokes, deep vein thrombosis (DVT), and pulmonary embolism (PE). Anticoagulant and antiplatelet drugs are essential in both treatment and prevention of thromboembolic events.
At Nirvana Pharma, we distribute a wide range of traditional agents (Warfarin, Heparin), low molecular weight heparins (LMWHs), direct oral anticoagulants (DOACs), and modern antiplatelet drugs trusted by hospitals, clinics, and cardiac centers.
📋 Anticoagulant Product Catalogue
Vitamin K Antagonist (VKA)
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Warfarin |
VKA |
Tab: 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg |
AF, DVT, PE, prosthetic valves |
Heparins & LMWHs
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Heparin (UFH) |
Indirect thrombin inhibitor |
Inj: 1000, 5000, 10,000 units/mL |
DVT, PE, ACS, dialysis |
| Enoxaparin |
LMWH |
Prefilled syringes: 20–100 mg |
DVT, ACS, perioperative prophylaxis |
| Dalteparin |
LMWH |
Inj: 2500–10,000 IU prefilled syringes |
DVT, ACS |
Parenteral Factor Xa Inhibitor
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Fondaparinux |
Factor Xa inhibitor |
Inj: 2.5, 5, 7.5, 10 mg prefilled |
DVT, PE prophylaxis |
Direct Oral Anticoagulants (DOACs)
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Rivaroxaban |
Factor Xa inhibitor |
Tab: 2.5, 10, 15, 20 mg |
AF, DVT, PE |
| Apixaban |
Factor Xa inhibitor |
Tab: 2.5, 5 mg |
AF, DVT, PE |
| Edoxaban |
Factor Xa inhibitor |
Tab: 15, 30, 60 mg |
AF, DVT, PE |
| Dabigatran etexilate |
Direct thrombin inhibitor |
Cap: 75, 110, 150 mg |
AF, DVT, PE |
Parenteral Direct Thrombin Inhibitors
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Bivalirudin |
Direct thrombin inhibitor |
Inj: 250 mg vial |
PCI, HIT |
| Argatroban |
Direct thrombin inhibitor |
Inj: 100 mg/mL |
HIT |
📋 Antiplatelet Product Catalogue
Cyclooxygenase (COX) Inhibitor
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Aspirin |
COX inhibitor (irreversible) |
Tab: 75, 81, 150, 300, 325, 500 mg |
ACS, stroke, secondary CV prevention |
P2Y12 Receptor Inhibitors
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Clopidogrel |
P2Y12 inhibitor |
Tab: 75, 300 mg |
ACS, stroke prevention, PCI |
| Prasugrel |
P2Y12 inhibitor |
Tab: 5, 10 mg |
ACS, PCI |
| Ticagrelor |
P2Y12 inhibitor |
Tab: 60, 90 mg |
ACS, PCI |
| Ticlopidine |
P2Y12 inhibitor (older) |
Tab: 250 mg |
Stroke prevention (rare) |
| Cangrelor |
IV P2Y12 inhibitor |
Inj: 50 mg vial |
PCI (rapid effect) |
Phosphodiesterase (PDE) Inhibitors
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Dipyridamole |
PDE inhibitor |
Tab: 25, 50, 75 mg |
Stroke prevention (with aspirin) |
| Cilostazol |
PDE3 inhibitor |
Tab: 50, 100 mg |
Intermittent claudication, PAD |
GPIIb/IIIa Receptor Antagonists
| Drug Name |
Classification |
Common Strengths (Dosage Forms) |
Primary Uses |
| Abciximab |
Monoclonal antibody |
IV: 2 mg/mL vials |
PCI, ACS |
| Eptifibatide |
Peptide inhibitor |
IV: 0.75 mg/mL |
ACS, PCI |
| Tirofiban |
Non-peptide inhibitor |
IV: 12.5 mg/50 mL, 25 mg/250 mL |
ACS, PCI |
Closing Note
Our anticoagulant and antiplatelet portfolio provides clinicians with trusted options ranging from traditional agents like Warfarin and Heparin to next-generation oral anticoagulants (DOACs) and modern platelet inhibitors (P2Y12 blockers, GPIIb/IIIa antagonists). Nirvana Pharma ensures authentic sourcing, cold-chain compliance where required, and reliable supply to support life-saving cardiovascular interventions.
